ReviewMolecular biology reports2026
Benzodiazepines for anxiety and depression: an updated overview of current use and major outcomes.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anxiety and depressive disorders are serious, debilitating health problems that negatively impact the patient's overall well-being and life satisfaction. The prevalence of these mood disorders has increased recently. Several treatment approaches against anxiety and depressive disorders are now available. For instance, pharmacological treatments, including the use of benzodiazepines (BZDs), have been increasingly documented. The present paper gives an insight into the underlying mechanisms of BZD anxiolytic abilities and points out the paramount role of some brain regions and systems in mediating this anxiolytic effect, and these include the HPA axis, the amygdala, and the hippocampus. Additionally, it aims to list and understand the mechanisms of adverse effects associated with these medications, including dependence, memory impairment, and withdrawal-associated symptoms, opening new perspectives in the design and production of other safe and more options for efficient medications.
Indexed as
Identifiers
42133215What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.